2. Liu S, Yao X, Zhang D, Sheng J, Wen X, Wang Q, et al. 2018; Analysis of transcription factor-related regulatory networks based on bioinformatics analysis and validation in hepatocellular carcinoma. Biomed Res Int. 2018:1431396. DOI:
10.1155/2018/1431396. PMID:
30228980. PMCID:
PMC6136478.
Article
3. Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. 2019; Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 120:10069–10081. DOI:
10.1002/jcb.28290. PMID:
30525236.
Article
6. Chuang HY, Ou YH. Abstract 4068: overexpression of anillin in colorectal cancer promotes the cell proliferation, cell mobility and cell invasion. Cancer Res. 2014; 74(19 Suppl):4068. DOI:
10.1158/1538-7445.AM2014-4068.
Article
7. Zhang LH, Wang D, Li Z, Wang G, Chen DB, Cheng Q, et al. 2021; Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 20:337–344. DOI:
10.1016/j.hbpd.2020.08.007. PMID:
32933876.
Article
8. Xu Z, Zhang Q, Luh F, Jin B, Liu X. 2019; Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer. Oncol Lett. 17:1865–1876. DOI:
10.3892/ol.2018.9762. PMID:
30675249. PMCID:
PMC6341836.
Article
9. Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, et al. 2017; High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 49:817–823. DOI:
10.1007/s11255-017-1545-7. PMID:
28213802.
Article
10. Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, et al. 2008; ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 14:4814–4820. DOI:
10.1158/1078-0432.CCR-07-5262. PMID:
18676753.
Article
11. Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, et al. 2020; BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med. 9:8159–8172. DOI:
10.1002/cam4.3411. PMID:
32977361. PMCID:
PMC7643650.
Article
12. Chai N, Xie HH, Yin JP, Sa KD, Guo Y, Wang M, et al. 2018; FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1. Biochem Biophys Res Commun. 500:924–929. DOI:
10.1016/j.bbrc.2018.04.201. PMID:
29705704.
Article
13. Zhao J, Han SX, Ma JL, Ying X, Liu P, Li J, et al. 2013; The role of CDK1 in apoptin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 30:253–259. DOI:
10.3892/or.2013.2426. PMID:
23619525.
Article
14. Zhou J, Han S, Qian W, Gu Y, Li X, Yang K. 2018; Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. Onco Targets Ther. 11:4451–4459. DOI:
10.2147/OTT.S167614. PMID:
30104887. PMCID:
PMC6074828.
Article
15. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N. 2000; Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology. 59:68–74. DOI:
10.1159/000012140. PMID:
10895070.
Article
16. Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, et al. 2015; Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer. 113:1735–1743. DOI:
10.1038/bjc.2015.378. PMID:
26554648. PMCID:
PMC4701993.
Article
17. Dai W, Miao H, Fang S, Fang T, Chen N, Li M. 2016; CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep. 14:1509–1514. DOI:
10.3892/mmr.2016.5410. PMID:
27314282. PMCID:
PMC4940071.
Article
18. Chen J, Xia H, Zhang X, Karthik S, Pratap SV, Ooi LL, et al. 2015; ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol. 62:1287–1295. DOI:
10.1016/j.jhep.2015.01.014. PMID:
25617497.
Article
19. Jin Y, Yu Y, Shao Q, Ma Y, Zhang R, Yao H, et al. 2014; Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients. Int J Clin Exp Pathol. 7:8724–8731. PMID:
25674238. PMCID:
PMC4313974.
20. He Z, Mei L, Connell M, Maxwell CA. 2020; Hyaluronan mediated motility receptor (HMMR) encodes an evolutionarily conserved homeostasis, mitosis, and meiosis regulator rather than a hyaluronan receptor. Cells. 9:819. DOI:
10.3390/cells9040819. PMID:
32231069. PMCID:
PMC7226759.
Article
21. Lin S, Zhou S, Jiang S, Liu X, Wang Y, Zheng X, et al. 2016; NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. Oncol Rep. 36:853–862. DOI:
10.3892/or.2016.4896. PMID:
27349376.
Article
22. Fu L, Liu S, Wang H, Ma Y, Li L, He X, et al. 2017; Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis. Cancer Biomark. 20:101–106. DOI:
10.3233/CBM-170586. PMID:
28759960.
Article
23. Yang QX, Zhong S, He L, Jia XJ, Tang H, Cheng ST, et al. 2019; PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett. 452:90–102. DOI:
10.1016/j.canlet.2019.03.028. PMID:
30914208.
Article
24. Wang Y, Shi F, Xing GH, Xie P, Zhao N, Yin YF, et al. 2017; Protein regulator of cytokinesis PRC1 confers chemoresistance and predicts an unfavorable postoperative survival of hepatocellular carcinoma patients. J Cancer. 8:801–808. DOI:
10.7150/jca.17640. PMID:
28382142. PMCID:
PMC5381168.
Article
25. Imaoka H, Toiyama Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, et al. 2015; RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 36:346–354. DOI:
10.1093/carcin/bgu327. PMID:
25568185.
Article
26. Wang SM, Ooi LL, Hui KM. 2011; Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res. 17:6040–6051. DOI:
10.1158/1078-0432.CCR-11-0557. PMID:
21825042.
Article
27. Nana AW, Wu SY, Yang YS, Chin YT, Cheng TM, Ho Y, et al. 2018; Nano-diamino-tetrac (NDAT) enhances resveratrol-induced antiproliferation by action on the RRM2 pathway in colorectal cancers. Horm Cancer. 9:349–360. DOI:
10.1007/s12672-018-0334-9. PMID:
30027502.
Article
28. Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK. 2014; High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver. 8:662–668. DOI:
10.5009/gnl13392. PMID:
25368754. PMCID:
PMC4215454.
Article
29. Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y, et al. 2020; Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 13:21. DOI:
10.3892/br.2020.1328. PMID:
32765860. PMCID:
PMC7403841.
Article
30. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, et al. 2009; TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 124:644–652. DOI:
10.1002/ijc.23968. PMID:
19003983.
Article